Medicago completes cGMP qualification of its manufacturing facility
"The qualification of our facility and quality control procedures to meet the cGMP and ISO standards are another important milestone in our program to advance our VLP pandemic influenza vaccine candidates," said Andy Sheldon, President and CEO of Medicago. "We are now in a position to take full advantage of our manufacturing capability and initiate the production of VLP vaccines this year to support our human clinical trials."
Medicago's facility is made up of 11,000 sq. ft. of Biosafety Level 2 greenhouse spaces for plant growth, as well as 3,000 sq. ft. of cGMP manufacturing suites for plant manipulation, product recovery and purification.
Most read news
Topics
Organizations
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.